Skip to main content
. 2020 Aug 25;10(4):168–177.

Figure 2.

Figure 2

[89Zr]Zr-rituximab activity measured in SUV in the spleen (triangle) and liver (asterisk) reference using the non-preload protocol, between treatment outcomes: non-responders (NR, n=4) and responders (RSP, n=6). There is significantly higher splenic activity measured in the NR group.